Prediction of Drug-Induced Liver Injury in HepG2 Cells Cultured with Human Liver Microsomes

Chemical Research in Toxicology

Volumn 28, Issue 5, 2015, Pages 872-885

  Choi, Jong Min ^a   Oh, Soo Jin ^b   Lee, Ji Yoon ^a   Jeon, Jang Su ^a   Ryu, Chang Seon ^a   Kim, Young Mi ^c   Lee, Kiho ^d   Kim, Sang Kyum ^a  

^a Chungnam National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Hanyang University   (South Korea)

^d Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; BAKUCHIOL; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DICLOFENAC; GLUCURONOSYLTRANSFERASE; IRBESARTAN; LEFLUNOMIDE; MELOXICAM; NEFAZODONE; PARACETAMOL; PHOSPHORAMIDE MUSTARD; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUDOXICAM; VALSARTAN; ALKYLATING AGENT; CYTOCHROME P450 3A; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; METABOLIC ACTIVATION; PREDICTION; TOXIC HEPATITIS; DRUG EFFECTS; LIVER; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP3A; DRUG-INDUCED LIVER INJURY; HEP G2 CELLS; HUMANS; LIVER; MICROSOMES, LIVER; NADP;

EID: 84929579986     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx500504n     Document Type: Article

References (46)

1. Kaplowitz, N. (2005) Idiosyncratic drug hepatotoxicity Nat. Rev. Drug Discovery 4, 489 - 499
2. Guengerich, F. P. and MacDonald, J. S. (2007) Applying mechanisms of chemical toxicity to predict drug safety Chem. Res. Toxicol. 20, 344 - 369
3. Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M., and Williams, D. P. (2005) The role of metabolic activation in drug-induced hepatotoxicity Annu. Rev. Pharmacol. Toxicol. 45, 177 - 202
4. Donato, M. T., Lahoz, A., Castell, J. V., and Gomez-Lechon, M. J. (2008) Cell lines: a tool for in vitro drug metabolism studies Curr. Drug Metab. 9, 1 - 11
5. Guillouzo, A. (1998) Liver cell models in in vitro toxicology Environ. Health Perspect 106 (Suppl. 2) 511 - 532
6. Aninat, C., Piton, A., Glaise, D., Le Charpentier, T., Langouet, S., Morel, F., Guguen-Guillouzo, C., and Guillouzo, A. (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells Drug Metab. Dispos. 34, 75 - 83
7. Doehmer, J., Dogra, S., Friedberg, T., Monier, S., Adesnik, M., Glatt, H., and Oesch, F. (1988) Stable expression of rat cytochrome P-450IIB1 cDNA in Chinese hamster cells (V79) and metabolic activation of aflatoxin B1 Proc. Natl. Acad. Sci. U.S.A. 85, 5769 - 5773
8. Gomez-Lechon, M. J., Donato, T., Jover, R., Rodriguez, C., Ponsoda, X., Glaise, D., Castell, J. V., and Guguen-Guillouzo, C. (2001) Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2 Eur. J. Biochem. 268, 1448 - 1459
9. Hosomi, H., Fukami, T., Iwamura, A., Nakajima, M., and Yokoi, T. (2011) Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation Drug Metab. Dispos. 39, 1388 - 1395
10. Rodriguez-Antona, C., Bort, R., Jover, R., Tindberg, N., Ingelman-Sundberg, M., Gomez-Lechon, M. J., and Castell, J. V. (2003) Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma Mol. Pharmacol. 63, 1180 - 1189
11. Sivertsson, L., Ek, M., Darnell, M., Edebert, I., Ingelman-Sundberg, M., and Neve, E. P. (2010) CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells Drug Metab. Dispos. 38, 995 - 1002
12. Otto, M., Hansen, S. H., Dalgaard, L., Dubois, J., and Badolo, L. (2008) Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity Cell Biol. Toxicol. 24, 87 - 99
13. Duthie, S. J., Coleman, C. S., and Grant, M. H. (1988) Status of reduced glutathione in the human hepatoma cell line, HEP G2 Biochem. Pharmacol. 37, 3365 - 3368
14. Goodyer, C. G., Rhani, Z., and Zheng, H. (2008) Expression of the hepatic specific V1 messenger ribonucleic acid of the human growth hormone receptor gene is regulated by hepatic nuclear factor (HNF)-4alpha2 and HNF-4alpha8 Mol. Endocrinol. 22, 485 - 500
15. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65, 55 - 63
16. Lee, K. S. and Kim, S. K. (2013) Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions J. Appl. Toxicol. 33, 100 - 108
17. Li, A. F., Shen, G. L., Jiao, S. Y., Li, H., and Wang, Q. (2012) Metabolic detoxification of bakuchiol is mediated by cytochrome P450 enzymes in human liver microsomes Beijing Daxue Xuebao, Yixueban 44, 431 - 436
18. Emoto, C., Murase, S., Sawada, Y., Jones, B. C., and Iwasaki, K. (2003) In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole Drug Metab. Pharmacokinet. 18, 287 - 295
19. Huang, Z., Roy, P., and Waxman, D. J. (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide Biochem. Pharmacol. 59, 961 - 972
20. Li, F., Patterson, A. D., Hofer, C. C., Krausz, K. W., Gonzalez, F. J., and Idle, J. R. (2010) Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics Biochem. Pharmacol. 80, 1063 - 1074
21. Born, S. L., Caudill, D., Smith, B. J., and Lehman-McKeeman, L. D. (2000) In vitro kinetics of coumarin 3,4-epoxidation: application to species differences in toxicity and carcinogenicity Toxicol. Sci. 58, 23 - 31
22. Smith, K. S., Smith, P. L., Heady, T. N., Trugman, J. M., Harman, W. D., and Macdonald, T. L. (2003) In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity Chem. Res. Toxicol. 16, 123 - 128
23. Shi, Q., Yang, X., Greenhaw, J., and Salminen, W. F. (2011) Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes Toxicol. Sci. 122, 579 - 586
24. Kalgutkar, A. S., Nguyen, H. T., Vaz, A. D., Doan, A., Dalvie, D. K., McLeod, D. G., and Murray, J. C. (2003) In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes Drug Metab. Dispos. 31, 1240 - 1250
25. Barbhaiya, R. H., Shukla, U. A., Kroboth, P. D., and Greene, D. S. (1995) Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam J. Clin. Psychopharmacol. 15, 320 - 326
26. Obach, R. S., Kalgutkar, A. S., Ryder, T. F., and Walker, G. S. (2008) In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam Chem. Res. Toxicol. 21, 1890 - 1899
27. Frampton, J. E. and Scott, L. J. (2009) Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension Am. J. Cardiovasc. Drugs 9, 309 - 330
28. Bourrié, M., Meunier, V., Berger, Y., and Fabre, G. (1999) Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes Drug Metab. Dispos. 27, 288 - 296
29. Chang, T. K., Weber, G. F., Crespi, C. L., and Waxman, D. J. (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes Cancer Res. 53, 5629 - 5637
30. McGill, M. R. and Jaeschke, H. (2013) Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis Pharm. Res. 30, 2174 - 2187
31. Daly, A. K., Aithal, G. P., Leathart, J. B., Swainsbury, R. A., Dang, T. S., and Day, C. P. (2007) Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes Gastroenterology 132, 272 - 281
32. Tang, W. (2003) The metabolism of diclofenac-enzymology and toxicology perspectives Curr. Drug Metab. 4, 319 - 329
33. Yan, Z., Li, J., Huebert, N., Caldwell, G. W., Du, Y., and Zhong, H. (2005) Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides Drug Metab. Dispos. 33, 706 - 713
34. Bort, R., Mace, K., Boobis, A., Gomez-Lechon, M. J., Pfeifer, A., and Castell, J. (1999) Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways Biochem. Pharmacol. 58, 787 - 796
35. Koga, T., Fujiwara, R., Nakajima, M., and Yokoi, T. (2011) Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes Drug Metab. Dispos. 39, 54 - 60
36. Stewart, D. E. (2002) Hepatic adverse reactions associated with nefazodone Can. J. Psychiatry 47, 375 - 377
37. Bauman, J. N., Frederick, K. S., Sawant, A., Walsky, R. L., Cox, L. M., Obach, R. S., and Kalgutkar, A. S. (2008) Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug Drug Metab. Dispos. 36, 1016 - 1029
38. Kalgutkar, A. S., Vaz, A. D., Lame, M. E., Henne, K. R., Soglia, J., Zhao, S. X., Abramov, Y. A., Lombardo, F., Collin, C., Hendsch, Z. S., and Hop, C. E. (2005) Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4 Drug Metab. Dispos. 33, 243 - 253
39. Rotzinger, S. and Baker, G. B. (2002) Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes Eur. Neuropsychopharmacol. 12, 91 - 100
40. Dykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C., Smith, A. R., and Will, Y. (2008) In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone Toxicol. Sci. 103, 335 - 345
41. Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J., Urda, E., and Mutlib, A. E. (2006) Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone Toxicol. Sci. 90, 451 - 459
42. von Moltke, L. L., Greenblatt, D. J., Granda, B. W., Grassi, J. M., Schmider, J., Harmatz, J. S., and Shader, R. I. (1999) Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions Psychopharmacology 145, 113 - 122
43. Katsura, H., Tsukiyama, R. I., Suzuki, A., and Kobayashi, M. (2001) In vitro antimicrobial activities of bakuchiol against oral microorganisms Antimicrob. Agents Chemother. 45, 3009 - 3013
44. Lim, S. H., Ha, T. Y., Kim, S. R., Ahn, J., Park, H. J., and Kim, S. (2009) Ethanol extract of Psoralea corylifolia L. and its main constituent, bakuchiol, reduce bone loss in ovariectomised Sprague-Dawley rats Br. J. Nutr. 101, 1031 - 1039
45. Rostom, A., Goldkind, L., and Laine, L. (2005) Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients Clin. Gastroenterol. Hepatol. 3, 489 - 498
46. Greene, D. S. and Barbhaiya, R. H. (1997) Clinical pharmacokinetics of nefazodone Clin. Pharmacokinet. 33, 260 - 275